Stem Cells International

Current Status and Perspectives of Human Mesenchymal Stem Cell Therapy 2021


Publishing date
01 Dec 2021
Status
Closed
Submission deadline
30 Jul 2021

Lead Editor

1The University of British Columbia, Vancouver, Canada

2University of Alberta, Edmonton, Canada

3University of Malaya, Kuala Lumpur, Malaysia

This issue is now closed for submissions.
More articles will be published in the near future.

Current Status and Perspectives of Human Mesenchymal Stem Cell Therapy 2021

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Human mesenchymal stem cells (hMSCs) hold tremendous potential in cell-based therapies and regenerative medicine. Utilizing hMSCs could eliminate the ethical and safety concerns related to the use of other types of stem cells, including human embryonic stem cells and human-induced pluripotent stem cells. hMSCs can be isolated from various tissues, including bone marrow, fat, amniotic fluid, and umbilical cord, etc. hMSCs are capable of differentiating from the major specialized cells of the tissue in which they resided, therefore helping to repair and regenerate damaged tissues and organs. With its regenerative and curative potential, hMSCs have been studied in numerous clinical settings, including musculoskeletal, vascular, respiratory, and cardiac diseases, etc. Nonetheless, while the outcomes of numerous preclinical and clinical studies support the potential of hMSCs in various clinical fields, multiple challenges are yet to be addressed to achieve successful clinical translations.

In view of the growing need for hMSCs, the aim of this Special Issue is to solicit original research articles and review articles, discussing the recent advances on the use of hMSCs in various clinical settings, which will help us to better understand their therapeutic impact. We also hope that this Special Issue highlights the importance of understanding all the steps required in developing stem cell therapy, including bioprocessing, safety and efficacy assessment, cell administration route, and delivery strategies. Submissions describing strategies to maximize the therapeutic efficacy of hMSCs are particularly encouraged.

Moreover, this Special Issue invites researchers, industrials, biomedical engineers, technologists, and healthcare professionals specialised in cell and molecular biology, regenerative medicine, and biotechnology to share their knowledge.

Potential topics include but are not limited to the following:

  • Mesenchymal stem cell therapy for musculoskeletal diseases
  • Mesenchymal stem cell therapy for vascular diseases
  • Mesenchymal stem cell therapy for respiratory diseases
  • Mesenchymal stem cell therapy for cardiac diseases
  • Bioprocessing of hMSCs (e.g. cryopreservation, cell expansion, or cell differentiation)
  • Evaluation of different delivery strategies and administration routes of hMSCs
  • Strategies to improve the safety and efficacy of hMSCs
Stem Cells International
 Journal metrics
Acceptance rate44%
Submission to final decision76 days
Acceptance to publication35 days
CiteScore7.200
Journal Citation Indicator0.770
Impact Factor5.443
 Submit

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.